OPKO Health, Inc. (NASDAQ:OPK – Get Rating) hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $1.47 and last traded at $1.48, with a volume of 39403 shares changing hands. The stock had previously closed at $1.59.
Analyst Upgrades and Downgrades
OPK has been the topic of a number of research analyst reports. Piper Sandler cut their target price on OPKO Health from $5.00 to $4.00 and set an “overweight” rating on the stock in a research report on Friday, August 5th. StockNews.com began coverage on shares of OPKO Health in a research note on Wednesday, October 12th. They issued a “sell” rating for the company.
OPKO Health Trading Up 2.0 %
The company’s 50 day simple moving average is $1.80 and its 200 day simple moving average is $2.32. The firm has a market cap of $1.16 billion, a price-to-earnings ratio of -3.41 and a beta of 1.67. The company has a debt-to-equity ratio of 0.09, a current ratio of 1.55 and a quick ratio of 1.28.
Insiders Place Their Bets
Hedge Funds Weigh In On OPKO Health
A number of institutional investors and hedge funds have recently modified their holdings of the company. Humankind Investments LLC acquired a new position in OPKO Health in the third quarter valued at $25,000. Zacks Investment Management acquired a new position in OPKO Health in the third quarter valued at $25,000. Aigen Investment Management LP acquired a new position in OPKO Health in the second quarter valued at $29,000. Susquehanna International Group Ltd. acquired a new position in OPKO Health in the third quarter valued at $35,000. Finally, Verition Fund Management LLC acquired a new position in OPKO Health in the second quarter valued at $36,000. Institutional investors and hedge funds own 27.83% of the company’s stock.
OPKO Health Company Profile
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services.
- Get a free copy of the StockNews.com research report on OPKO Health (OPK)
- Institutional Support for Analog Devices Remains High
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Three CBD Stocks to Dominate a Budding Industry
- Is the 60/40 Portfolio Mix Still in Vogue?
- Microsoft Shares: Is it Time to Back Up the Truck?
Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.